Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

487 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker.
Ronner E, Boersma E, Akkerhuis KM, Harrington RA, Lincoff AM, Deckers JW, Karsch K, Kleiman NS, Vahanian A, Topol EJ, Califf RM, Simoons ML. Ronner E, et al. Among authors: kleiman ns. Eur Heart J. 2002 Feb;23(3):239-46. doi: 10.1053/euhj.2001.2736. Eur Heart J. 2002. PMID: 11792139 Clinical Trial.
Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Steering Committee.
Topol EJ, Armstrong P, Van de Werf F, Kleiman N, Lee K, Morris D, Simoons M, Barbash G, White H, Califf RM. Topol EJ, et al. J Am Coll Cardiol. 1992 May;19(6):1123-8. doi: 10.1016/0735-1097(92)90312-b. J Am Coll Cardiol. 1992. PMID: 1564212 Free article. Clinical Trial.
Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention.
Harrington RA, Kleiman NS, Kottke-Marchant K, Lincoff AM, Tcheng JE, Sigmon KN, Joseph D, Rios G, Trainor K, Rose D, et al. Harrington RA, et al. Among authors: kleiman ns. Am J Cardiol. 1995 Dec 15;76(17):1222-7. doi: 10.1016/s0002-9149(99)80345-2. Am J Cardiol. 1995. PMID: 7503000 Clinical Trial.
Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Holmes DR Jr, Bates ER, Kleiman NS, Sadowski Z, Horgan JH, Morris DC, Califf RM, Berger PB, Topol EJ. Holmes DR Jr, et al. Among authors: kleiman ns. J Am Coll Cardiol. 1995 Sep;26(3):668-74. doi: 10.1016/0735-1097(95)00215-p. J Am Coll Cardiol. 1995. PMID: 7642857 Free article. Clinical Trial.
Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators.
Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJ, et al. Tcheng JE, et al. Among authors: kleiman ns. Circulation. 1995 Apr 15;91(8):2151-7. doi: 10.1161/01.cir.91.8.2151. Circulation. 1995. PMID: 7697843 Clinical Trial.
Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Kleiman NS, White HD, Ohman EM, Ross AM, Woodlief LH, Califf RM, Holmes DR Jr, Bates E, Pfisterer M, Vahanian A, et al. Kleiman NS, et al. Circulation. 1994 Dec;90(6):2658-65. doi: 10.1161/01.cir.90.6.2658. Circulation. 1994. PMID: 7994805 Clinical Trial.
487 results